Comparison
BPC-157, TB-500, GHK-Cu and KLOW compared
A useful comparison begins with the outcome being claimed. Hair count, tendon mechanics and a safety blood test answer different questions.
Studies and outcomes
| Subject | Experiment in this collection | Finding and boundary |
|---|---|---|
| BPC-157 | Transected Achilles tendon in Wistar rats | Better mechanical, functional and tissue recovery; a rat tendon endpoint. |
| Full-length thymosin β4 | Embolic stroke in male Wistar rats | Neurological improvement at 2 and 12 mg/kg; no significant benefit at 18 mg/kg. |
| TB-500 fragment | Musculoskeletal peptide review | Scarce rigorous human safety evidence; parent-protein findings need separate validation for the fragment. |
| GHK-containing combination | Six-month trial in 45 men with androgenetic alopecia | Hair counts increased versus placebo; the preparation also contained 5-aminolevulinic acid. |
| KPV | Cultured intestinal and immune cells, plus mouse colitis | Reduced inflammatory signalling and mouse colitis severity; KLOW was not tested. |
| KLOW | No controlled blend study in the supplied record | Combination benefit and safety remain unmeasured. |
Safety studies
The BPC-157 intravenous pilot involved two healthy adults. The full-length thymosin β4 Phase 1 study involved 40 healthy volunteers. Both reported reassuring tolerability observations within their designs. Neither tested whether an injured human tendon, bone or cartilage recovered better.
I resist ranking those studies by headcount and then calling the winner a better treatment. They tested different molecules and questions. A topical cosmetic result for GHK-Cu also has a different route and purpose from a systemic peptide claim. The skin-delivery discussion explains why that distinction matters physically.
Which claim needs another experiment?
For cartilage restoration, this collection has no blinded human trial showing the claimed outcome. For the TB-500 fragment, the parent protein's evidence leaves fragment-specific efficacy and safety open. For KLOW, even the proposed advantage over a component alone awaits a controlled comparison.
I’d put the most useful next experiments at those exact gaps. Repeating that something supports repair adds little when the unresolved question is whether the tested preparation improves a particular human outcome. The BPC-157 musculoskeletal review and the wider sports-medicine review both describe the shortage of rigorous human evidence.